Indolfi Cristiana, Grella Carolina, Klain Angela, Dinardo Giulio, Colosimo Simone, Piatto Dario, Nespoli Claudia, Perrotta Alessandra, Miraglia Del Giudice Michele
Department of Woman, Child and General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Life (Basel). 2025 Feb 27;15(3):375. doi: 10.3390/life15030375.
Atopic dermatitis (AD) is a chronic inflammatory skin disorder with significant implications for patient quality of life and a well-documented association with the atopic march. Recent advancements in biomarker research have unveiled critical insights into AD pathogenesis, diagnosis, prognosis, and therapeutic monitoring. This comprehensive review evaluates the utility of emerging biomarkers, including cytokines, chemokines, genetic markers, and microbiome-related components, in understanding the disease mechanisms and stratifying patient care. The role of minimally invasive diagnostic techniques, such as tape stripping and RNA monitoring, is highlighted, offering innovative approaches to pediatric populations. Furthermore, this review explores the biomarkers that predict disease progression, therapeutic response, and comorbidities, including food allergies and asthma. Personalized treatment strategies based on endotype-specific biomarkers are discussed as a future direction for improving clinical outcomes. Despite promising findings, the integration of biomarkers into routine practice necessitates further validation through large-scale studies. This work underscores the transformative potential of biomarker-driven approaches in enhancing the management of AD in children and its associated conditions.
特应性皮炎(AD)是一种慢性炎症性皮肤病,对患者生活质量有重大影响,并且与特应性进程有充分记录的关联。生物标志物研究的最新进展揭示了对AD发病机制、诊断、预后和治疗监测的关键见解。这篇综述全面评估了新兴生物标志物的效用,包括细胞因子、趋化因子、遗传标志物和微生物组相关成分,以了解疾病机制并对患者护理进行分层。强调了微创诊断技术的作用,如胶带剥离和RNA监测,为儿科人群提供了创新方法。此外,本综述探讨了预测疾病进展、治疗反应和合并症(包括食物过敏和哮喘)的生物标志物。基于内型特异性生物标志物的个性化治疗策略作为改善临床结果的未来方向进行了讨论。尽管有令人鼓舞的发现,但将生物标志物整合到常规实践中仍需要通过大规模研究进行进一步验证。这项工作强调了生物标志物驱动方法在加强儿童AD及其相关病症管理方面的变革潜力。